Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹2,282.90
15.70 (0.69%)
High VOLATILITY
As on 10 Jul 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹64.42K Cr
MID CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
47.0
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹1,792.6+27.4%
52W High₹2,474-7.7%
Current Price
₹2,282.90
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹1,826.32
Upper Circuit₹2,739.48
Reference Price
₹2,282.90
Investment Checklist
Inverse Head and Shoulders on 1W (BREAKOUT CONFIRMED) — target ₹2504.1
Double Bottom on 1W (BREAKOUT CONFIRMED) — target ₹2485.3
Trend: Price above all key MAs — strong uptrend
Composite score 49.93 (BUY) with 53.7% confidence
SuperTrend(10,3): Price below SuperTrend (Industry Standard (Swing/Medium-Term))
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Confidence
54%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend
EMA20
2221.27
EMA50
2223.79
EMA200
2125.32
Price Action
UPTREND
BULLISH
Higher Highs7
Higher Lows6
Lower Highs2
Lower Lows3
Support & Resistance Levels
Resistance (Above)
₹2291.35
₹2427.00
₹2474.00
Support (Below)
₹2242.45
₹2204.80
₹2156.94
₹2087.27
₹2026.10
Volume Analysis
TrendINCREASING
Change+36.80%
Unusual VolumeNo
Stop Loss Levels
Fixed Risk
1% Risk₹2260.07
3% Risk₹2214.41
5% Risk₹2168.76
7% Risk (Custom)
₹2123.10Technical Levels
1x ATR (Volatility)₹2220.32
2x ATR (Swing)₹2157.74
3x ATR (Trend)₹2095.16
Immediate Support₹2242.45
Moving Averages
EMA 9 (Short-term)₹2238.74
EMA 20 (Medium-term)₹2221.27
EMA 50 (Trend)₹2223.79
EMA 200 (Long-term)₹2125.32
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹3,220.1 Cr | ₹3,059.3 Cr | ₹6,003.8 Cr | ₹3,888 Cr |
| Net Profit | ₹4.7 Cr | ₹46.9 Cr | ₹610.4 Cr | ₹403.2 Cr |
| EPS | — | ₹1.66 | ₹21.63 | ₹14.29 |
| Operating Profit | ₹199.9 Cr | ₹283.7 Cr | ₹1,175.1 Cr | ₹729.9 Cr |
ROE
11.83%
ROCE
14.19%
Debt/Equity
0.28
Current Ratio
1.56
OPM
18.77%
NPM
10.37%
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| Glenmark Pharmaceuticals Limited | ₹2,282.90 | +0.69% | 47.0 | ₹64.42K Cr mid Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 03 Oct 2025 | Interim Dividend - Rs 2.50 Per Share | INTERIM_DIVIDEND |
| 15 Sept 2025 | Dividend - Rs 2.50 Per Share | DIVIDEND |
| 13 Sept 2024 | Dividend - Rs 2.50 Per Share | DIVIDEND |
| 18 Sept 2023 | Dividend - Rs 2.50 Per Share | DIVIDEND |
| 12 Sept 2022 | Annual General Meeting/Dividend - Rs 2.50 Per Share | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for GLENMARK
View All
positive
ET Markets - Stocks 3d ago
Stocks in news: Adani Enterprises, Cochin Shipyard, IDFC First Bank, Premier Energies, Glenmark Pharma
Markets traded subdued on the weekly expiry day, with indices ending marginally lower. Cochin Shipyard's offer for sale saw strong investor demand on its first day. Adani Enterprises' US legal case faces a likely dismissal by federal prosecutors. IDFC First Bank launched provident fund payment services through its EPFO integration. Premier Energies secured significant orders, and Glenmark Pharma launched a generic drug in the US.
ADANIENTBANKADDBANKBETFBANKETFBANKINDIABANKPSUBBNPNBETFBNKETFAXISCOCHINSHIPEBANKNIFTYECAPINSUREFEDERALBNKFINIETFGLENMARKGOLD1GOLDBETAGROWWCAPMGROWWPSUBKHDFCGOLDHDFCPSUBKHDFCPVTBANIDFCFIRSTBIVZINGOLDIVZINNIFTYLICMFGOLDLICNETFN50LICNETFSENMIDCAPBETANETFNEXT50BETANPBETPHARMABEESPREMIERPREMIERENEPSUBANKADDPSUBNKIETFPVTBANKADDQGOLDHALFSBIBPBSBIETFPBSILVERBETATATAGOLDTATSILVTNIDETFCapital GoodsFinancial Services
positive
LiveMint - Companies 3d ago
Beyond generics: Glenmark resets agenda with a bold 10-year pivot to global drug innovation, says chairman Saldanha
For chairman Glenn Saldanha, the way forward is a mix of licensing deals, partnerships and Glenmark’s own commercialization in emerging markets.
GLENMARKGLOBALConsumer ServicesHealthcare
neutral
NDTV Profit 4d ago
Five Stocks To Buy: Adani Power, Glenmark Pharma, Tata Steel And More | July 7, 2026
Market analysts and brokerage firms have identified high-conviction trading ideas for the upcoming session, focusing on power, pharma, auto sector and chemicals.
ABHAPOWERADANIENTADANIPOWERGLENMARKGVPILJGCHEMMSPLSALSTEELTATACHEMTATAPOWERTATASTEELTATATECHTECILCHEMCapital GoodsChemicals